Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2019 16:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results

-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA)...
March 21, 2019 16:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations

-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical...
March 14, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today reported the Company’s financial results...
March 05, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference

WESTLAKE VILLAGE, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield...
February 20, 2019 08:01 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Prices Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten...
February 19, 2019 16:10 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that it has commenced a...
February 08, 2019 09:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System

-- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solutionof silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has...
January 02, 2019 16:30 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference

WESTLAKE VILLAGE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief...
December 06, 2018 16:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference

WESTLAKE VILLAGE, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that Frederick...
December 03, 2018 07:05 ET | Source: Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019

-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right